Phathom Pharmaceuticals (PHAT) Interest Expenses (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Interest Expenses of $25.5 million for Q2 2026, up 1.04% year-over-year from $25.3 million in Q2 2025, and down 25.38% quarter-over-quarter from $34.2 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Interest Expenses (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Interest Expenses for 9 consecutive years, with $25.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Expenses rose 1.04% year-over-year to $25.5 million; the TTM figure through Jun 2026 stood at $25.5 million (up 1.04% YoY), while the FY2025 annual figure was $305.6 million, up 19.69% from the prior year.
- Interest Expenses eased to $25.5 million in Q2 2026 per PHAT's latest filing, from $34.2 million in the prior quarter.
- Across five years, Interest Expenses topped out at $51.6 million in Q3 2024 and bottomed at -$36.1 million in Q4 2024.
- Historically, Interest Expenses has averaged $16.4 million across 5 years, with a median of $16.8 million in 2024.
- Annual changes were most pronounced in 2023 — Interest Expenses soared 1301.81% — and 2024, when it tumbled 223.0%.
- Phathom Pharmaceuticals' Interest Expenses stood at $2.1 million in 2022, then jumped by 1301.81% to $29.4 million in 2023, then sank by 223.0% to -$36.1 million in 2024, then surged by 145.45% to $16.4 million in 2025, then surged by 55.56% to $25.5 million in 2026.
- Business Quant data shows PHAT's Interest Expenses at $25.5 million in Q2 2026, $34.2 million in Q1 2026, and $16.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 25.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.54 Mn |
| Jun 30, 2026 | 25.54 Mn |
| Mar 31, 2026 | 34.23 Mn |
| Mar 31, 2026 | 34.23 Mn |
| Dec 31, 2025 | 5.43 Mn |
| Dec 31, 2025 | 5.43 Mn |
| Sep 30, 2025 | 41.35 Mn |
| Sep 30, 2025 | 41.35 Mn |
| Jun 30, 2025 | 25.28 Mn |
| Jun 30, 2025 | 25.28 Mn |
| Mar 31, 2025 | 18.07 Mn |
| Mar 31, 2025 | 18.07 Mn |
| Dec 31, 2024 | 18.59 Mn |
| Dec 31, 2024 | 18.59 Mn |
| Sep 30, 2024 | 51.61 Mn |
| Sep 30, 2024 | 51.61 Mn |
| Jun 30, 2024 | 17.76 Mn |
| Jun 30, 2024 | 17.76 Mn |
| Mar 31, 2024 | 17.17 Mn |
| Mar 31, 2024 | 17.17 Mn |